Patient Characteristics
tumor
TUMOR PROGRESSION, GIST, TUMOR
From September 2018 to October 2020, 64 patients from 9 Chinese medical centers were enrolled in this study. The median age at the time of study entry was 57 years (range, 24-73 years). Forty-six patients (71.9%) were men, and 49 (76.6%) patients had ECOG performance status 1. All the patients had tumor progression after imatinib treatment failure. Among them, 3 patients withdrew from the study before completing one cycle of treatment, 61 patients completed tumor assessment. Fifty-six patients received KIT/PDGFRA genotype examination (Clinicopathological characteristics of all the patients receiving anlotinib.Remarks: There were some patients with multiple exon mutations, so the total percentage is greater than 100.In addition, we collected the data of sunitinib second-line therapy during anlotinib trial in study centers as historical retrospective data. Sixty one patients with metastatic GIST received sunitnib second-line therapy from September 2018 to October 2020.